Atenei associati alla CRUI

Del Zompo Maria - Rettore Università di Cagliari

  • Ateneo: Cagliari
  • Scad.: Scadenza 31 ottobre 2021
  • Ord.: Farmacologia
  • Nato: 21 aprile 1951 Cagliari
  • Sede: Via Università, 40 - 09124 Cagliari
  • Tel.: Tel. 070-659670 Fax 070-669425
  • Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Maria Del Zompo è nata a Cagliari il 21 Aprile 1951, ha conseguito la Maturità Classica nel 1969, si è laureata in Medicina e Chirurgia presso l’Università degli Studi di Cagliari nel 1975, e si è specializzata in Neurologia presso l’Università degli Studi di Cagliari nel 1980. 

Professore Ordinario in Farmacologia (SSD Bio/14) presso la Facoltà di Medicina e Chirurgia dell’Università di Cagliari – dal 2000 a tutt’oggi. 

2012 - oggi: Direttore del Dipartimento di Scienze Biomediche, Università degli Studi di Cagliari. 

2011 - oggi: Associata all’Istituto di Neuroscienze del CNR relativamente alla Commessa “Neurobiologia delle Dipendenze”.
2008 – oggi: Direttore della Scuola di Specializzazione in Farmacologia Medica, Facoltà di Medicina e Chirurgia, Università di Cagliari.
2007-2011: Direttore del Dipartimento di Neuroscienze “B.B. Brodie”, Università degli Studi di Cagliari
2005-2007: Pro-Rettore dell’Università degli Studi di Cagliari
2002-2008: Direttore della Scuola di Specializzazione in Farmacologia, Facoltà di Medicina e Chirurgia, Università degli Studi di Cagliari
2002-2012: Responsabile del Servizio Informazione e Formazione sul Farmaco
2002-oggi: Componente del Centro di Eccellenza per la Ricerca “Neurobiologia delle Tossicodipendenze”
2000-oggi: Direttore della Unità Complessa di Farmacologia Clinica, Azienda Ospedaliero-Universitaria di Cagliari
2000-oggi: Professore Ordinario di Farmacologia, Facoltà di Medicina e Chirurgia, Università degli Studi di Cagliari
1999-oggi: Docente nel Dottorato di Ricerca in Neuroscienze, Università degli Studi di Cagliari.
1995-oggi: Responsabile del Centro di Psicofarmacologia Clinica e del Centro Cefalee Primitive, Dipartimento di Scienze Biomediche (ex-Dipartimento di Neuroscienze “B.B. Brodie”), Università di Cagliari
1993-2012: Responsabile della Sezione di Farmacologia Clinica, Dipartimento di Scienze Biomediche (ex-Dipartimento di Neuroscienze “B.B. Brodie”), Università degli Studi di Cagliari
1992-2000: Professore Associato di Farmacologia presso la Facoltà di Medicina e Chirurgia, Università degli Studi di Cagliari
1987-1992: Ricercatore presso il Dipartimento di Neuroscienze “B.B. Brodie”, Università degli Studi di Cagliari
1980-1986: Ricercatore presso l’Istituto di Farmacologia, Università degli Studi di Cagliari
1979-1982:Borsista presso la Biological Psychiatry Branch, NIMH, Bethesda, MD (USA), diretta da Prof. Robert M Post
1976-1979: Assistente Incaricato presso la Clinica delle Malattie Nervose e Mentali, Università degli Studi di Cagliari
1975: Laurea in Medicina e Chirurgia
1969: Maturità classica
Nel 1982: Vincitrice del premio “Burroughs Wellcome Stipend Award”, Burroughs Wellcome Fund, Research Triangle Park, NC (USA) presso la Biological Psychiatry Branch, NIMH, Bethesda, MD (USA), diretta da Robert M Post, nel laboratorio diretto da John Tallman.

Dal 2 aprile 2015 è Rettore dell’Università degli Studi di Cagliari

Scadenza mandato Rettore: 31 ottobre 2021

Altri incarichi
Premio “Donna dell’Anno”, istituito dalla Delegazione Sardegna della “Associazione Imprenditrici e Donne Dirigenti di Azienda” (AIDDA), nel 2007.
Premio “Eleonora D’Arborea”, istituito dall’International Inner Wheel Club di Cagliari, nel 2000.
Premio “Burroughs Wellcome Stipend Award”, Burroughs Wellcome Fund, Research Triangle Park, NC (USA) nel 1981.
Membro della Commissione Ricerca e Sviluppo della Agenzia Italiana del Farmaco (AIFA), dal 2005.
Componente dell’Albo degli Esperti del Comitato di Indirizzo per la Valutazione della Ricerca (CIVR), dal 2004.
Membro della Commissione per il Prontuario Terapeutico Provinciale, dal 2003.
Componente del Centro di Eccellenza per la Neurobiologia delle Tossicodipendenze dal 2002

Attività scientifiche e pubblicazioni
Referee di numerose riviste internazionali tra cui Acta Psychiatrica Scandinavica, American Journal of Medical Genetics (Neuropsychiatric Genetics), Annals of Neurology, Biological Psychiatry, Brain Research Bulletin, Headache, Journal of Affective Disorders, Molecular Psychiatry, New England Journal of Medicine, Progress in Neuropsychopharmacology and Biological Psychiatry, American Journal of Psychiatr 

Editore di un numero monografico di Pharmacological Research sulla Farmacogenomica.

Collaborazioni scientifiche in corso:
 Ming Ta Michael Lee, Laboratory for International Alliance on Genomic Research Core for Genomic Medicine, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
 Martin Alda, Department of Psychiatry, Dalhousie University, Halifax, Canada.
 Gustavo Turecki, Research and Academic Affairs, Department of Psychiatry, McGill University, Montreal, Canada.
 Micahel Bauer, Dept. of Psychiatry and Psychotherapy, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
 Francis McMahon, Direttore dell’Unità “Genetic Basis of Mood and Anxiety Disorders”, National Institute of Mental Health, Bethesda, MD (USA).
 Thomas G. Schulze, Direttore della Sezione di Genetica Psichiatrica, Dipartimento di Psichiatria e Psicoterapia, University Medical Center, Georg-August-Universität, Göttingen, Germania.George P. Patrinos, Erasmus University Medical Center, Rotterdam, The Netherlands.
 Stefano Calza, Dipartimento di Scienze Biomediche e Biotecnologie, Università di Brescia.

Membro delle seguenti Società Scientifiche:
 International Society of Psychiatric Genetics (ISPG) (membro del Consiglio Direttivo)
 Società Italiana di Farmacologia (membro del Consiglio Direttivo della Sezione di Farmacologia Clinica fino al 2003)
 Consiglio Direttivo del Collegio Nazionale dei Farmacologi Universitari (concluso nel 2006)
 Società Italiana di Psichiatria Biologica
 Società Italiana di Neuropsicofarmacologia
 Società Italiana di Neuroscienze
 Society for Neuroscience (USA)
 World Federation of Societies of Biological Psychiatry
 International Society of Pharmacovigilance (ISOP)

Pubblicazioni internazionali
 Bocchetta A et al. Renal function during long-term lithium treatment: a cross-sectional and longitudinal study. BMC Medicine2015; 13:12 [abs]
 Hunsberger JG et al. Novel integrative genomic tool for interrogating lithium response in bipolar disorder. Translational Psychiatry 2015; 5: e504 [abs]
 International Genomics of Alzheimer’s Disease Consortium (IGAP). Convergent genetic and expression data implicate immunity in Alzheimer’s disease. Alzheimer’s and Dementia 2014 Dec 20. pii: S1552-5260(14)02492-3. [Epub ahead of print] [abs]
 Bauer M et al. Influence of birth cohort on age of onset cluster analysis in bipolar I disorder. European Psychiatry 2015; 30: 99-105 [abs]
 Niola P et al. Lithium-induced differential expression of SAT1 in suicide completers and controls is not correlated with polymorphisms in the promoter region of the gene. Psychiatry Research 2014; 220: 1167-1168.
 Bauer M et al. Relationship between sunlight and the age of onset of bipolar disorder: an international multisite study. J Affect Disord 167: 104-11, 2014. [abs]
 Escott-Price V et al. Gene-wide analysis detects two new susceptibility genes for Alzheimer’s disease. PLoS One 9: e94661, 2014. [abs]
 Floris G et al. C9ORF72 repeat expansion and bipolar disorder – is there a link? No mutation detected in a Sardinian cohort of patients with bipolar disorder. Bipolar Disorders 16: 667-8, 2014.
 Del Zompo M et al. Association study in three different populations between the GPR88 gene and major psychoses. Mol Genet Genomic Med 2: 152-9, 2014. [abs]
 Deiana V et al. Continuation versus discontinuation of lithium during pregnancy: a retrospective case series. J Clin Psychopharmacol 34: 407-10, 2014.
 Lambert JC et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nature Genetics 45: 1452-8, 2013. [abs]
 Pisanu C et al. No association of endocannabinoid genes with bipolar disorder or lithium response in a Sardinian sample”. Psychiatry Res 210: 887-90, 2013. [abs]
 Manchia M et al. Assessment of Response to Lithium Maintenance Treatment in Bipolar Disorder: A Consortium on Lithium Genetics (ConLiGen) Report. PLoS One 8: e65636, 2013. [abs]
 Squassina A et al. Differential effect of lithium on spermidine/spermine N1-acetyltransferase expression in suicidal behaviour. Int J Neuropsychopharmacol 16: 2209-18, 2013. [abs]
 Manchia M et al. Genetic risk of suicidal behavior in bipolar spectrum disorder: analysis of 737 pedigrees. Bipolar Disorders 15: 496-506, 2013. [abs]
 Squassina A et al. Insulin-like growth factor 1 (IGF-1) expression is up-regulated in lymphoblastoid cell lines of lithium responsive bipolar disorder patients. Pharmacol Res 73: 1-7, 2013. [abs]
 Severino G et al. Pharmacogenomics of bipolar disorder. Pharmacogenomics 14: 655-674, 2013. [abs]
 Bocchetta A et al. Duration of lithium treatment is a risk factor for reduced glomerular function: a cross-sectional study. BMC Medicine 11: 33, 2013. [abs]
 Costa M et al. Investigation of endocannabinoid system genes suggests association between peroxisome proliferator activator receptor-α gene (PPARA) and schizophrenia. European Neuropsychopharmacology 23: 749-59, 2013. [abs]
 Lambert JC et al. Genome-wide haplotype association study identifies the FRMD4A gene as a risk locus for Alzheimer’s disease. Mol Psychiatry 18: 461-470, 2013. [abs]
 Stochino ME et al. Evaluation of lithium response in episodic cluster headache: a retrospective case series. Headache 52: 1171-1175, 2012. [abs]
 Bauer M et al. Impact of sunlight on the age of onset of bipolar disorder. Bipolar Disorders 14: 654-663, 2012. [abs]
 Squassina A et al. Evidence for association of an ACCN1 gene variant with response to lithium treatment in Sardinian patients with bipolar disorder. Pharmacogenomics 12: 1559-1569, 2011. [abs]
 Deiana V et al. A retrospective case series of bipolar patients with adjunctive carbamazepine in long-term lithium treatment: evaluation of the effectiveness. J Clin Psychopharmacol 31: 538-540, 2011.
 Genin E et al. APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Molecular Psychiatry 16: 903-907, 2011. [abs]
 Squassina A. et al. Age at onset in bipolar disorder: Investigation of the role of TaqIA polymorphism of DRD2 gene in a Sardinian sample. European Psychiatry 26: 141-143, 2011. [abs]
 Lambert JC et al. Evidence of the association of BIN1 and PICALM with the AD risk in contrasting European populations. Neurobiol Aging 32: 756.e11-5, 2011. [abs]
 Tozzi F et al. Admixture analysis of age at onset in bipolar disorder. Psychiatry Research 185: 27-32, 2011. [abs]
 Squassina A, Manchia M, Del Zompo M. Pharmacogenomics of mood stabilizers in the treatment of bipolar disorder. Human Genomics and Proteomics, 159761, 2010. [abs]
 Lambert JC et al. The CALHM1 P86L polymorphism is a genetic modifier of age at onset in Alzheimer’s disease: a meta-analysis study. Journal of Alzheimers Disease 22: 247-255, 2010. [abs]
 Squassina A et al. Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice. Pharmacogenomics 11: 1149-1167, 2010. [abs]
 Del Zompo M et al. Genome-scan for bipolar disorder with sib-pair families in the Sardinian population: a new susceptibility locus on chromosome 1p22-p21?. Am J Med Genet B Neuropsychiatr Genet 153B: 1200-1208, 2010. [abs]
 Schulze TG et al. The International Consortium on Lithium Genetics (ConLiGen): an initiative by the NIMH and IGSLI to study the genetic basis of response to lithium treatment. Neuropsychobiology 62: 72-78, 2010. [abs]
 Asuni C et al. Mixture analysis of age at onset in migraine without aura: evidence for three subgroups. Headache 50: 1313-1319, 2010. [abs]
 Squassina A et al. NRG1 and BDNF genes in schizophrenia: an association study in an Italian case-control sample. Psychiatry Research 176: 82-84, 2010. [abs]
 Manchia M et al. Interacting genes in lithium prophylaxis: preliminary results of an exploratory analysis on the role of DGKH and NR1D1 gene polymorphisms in 199 Sardinian bipolar patients. Neuroscience Letters 467: 67-71, 2009. [abs]
 Manchia M et al. No association between lithium full responders and the DRD1, DRD2, DRD3, DAT1, 5-HTTLPR and HTR2A genes in a Sardinian sample. Psychiatry Research 169: 164-166, 2009. [abs]
 Asuni C et al. Migraine and tumour necrosis factor gene polymorphism. An association study in a Sardinian sample. Journal of Neurology 256: 194-197, 2009. [abs]
 Squassina A et al. The diacylglycerol kinase eta (DGKH) gene and bipolar disorder: a replication study in a Sardinian sample. Molecular Psychiatry 14: 350-351, 2009.
 Severino G et al. Association study in a Sardinian sample between Bipolar Disorder and the nuclear receptor REV-ERBα gene, a critical component of the circadian clock system. Bipolar Disorders 11: 215-220, 2009. [abs]
 Squassina A. et al. A case-control association study of the PDLIM5 gene and bipolar disorder in a Sardinian sample. Psychiatric Genetics 18: 128-132, 2008 [abs]
 Squassina A et al. The PDLIM5 gene and lithium prophylaxis: An association and gene expression analysis in Sardinian patients with bipolar disorder. Pharmacological Research 57: 369-73, 2008 [abs]
 Manchia M et al. Age at onset in Sardinian bipolar I patients: evidence for three subgroups. Bipolar Disorders 10: 443-446, 2008 [abs]
 Bocchetta A et al. Long term lithium treatment and survival from external causes including suicide. J Clin Psychopharmacol 27: 544-546, 2007 [abs]
 Piccardi MP et al. Alzheimer’s disease: case-control association study of polymorphisms in ACHE, CHAT, and BCHE genes in a Sardinian sample. American Journal of Medical Genetics Part B (Neuropsychiatric Genetics) 144: 895-899, 2007 [abs]
 Asuni C et al. Association study between clinical response to rizatriptan and some candidate genes. J Headache Pain 8: 185-9, 2007 [abs]
 Bocchetta A et al. Fifteen-year follow-up of thyroid function in lithium patients”. J Endocrinol Invest 30: 363-366, 2007 [abs]
 Del Zompo M et al. Haplotype association study between DRD1 gene and bipolar type I affective disorder in two samples from Canada and Sardinia”. American Journal of Medical Genetics Part B (Neuropsychiatric Genetics) 144B: 237-241, 2007 [abs]
 Ghiani ME et al. Genetic, demographic and archival study on a Sardinian village. In: Human Genetic Isolates, eds. C. Calò and G. Vona, Research Signpost, Kerala (India); pp. 131-149, 2006.
 Galderisi S et al. COMT VAL158Met and BDNF C270T polymorphisms in schizophrenia: associations with cognitive and motor impairment. Neuropsychobiology 52: 83-89, 2005 [abs]
 Severino G et al. A48G polymorphism in the D1 receptor genes associated with bipolar I disorder. American Journal of Medical Genetics (Neuropsychiatric Genetics) 134B: 37-38, 2005 [abs]
 Galderisi S et al. COMT VAL158Met and BDNF C270T polymorphisms in schizophrenia: a case-control study. Schizophrenia Research 73: 27-30, 2005 [abs]
 Severino G et al. Adverse drug reactions during imatinib and lansoprazole treatment in GIST. The Annals of Pharmacotherapy 39: 162-164, 2005 [abs]
 Severino G, Del Zompo M. Adverse drug reactions: role of pharmacogenomics. Pharmacological Research 49: 363-373, 2004 [abs]
 Cousin E et al. Association studies in candidate genes: strategies to select SNPs to be tested. Human Heredity 56: 151-159, 2003.
 Stochino ME et al. Association study between the phenotype migraine without aura – panic disorder and dopaminergic receptor genes. Pharmacological Research 48: 531-534, 2003 [abs]
 Severino G et al. Pharmacogenomics: state of the research and perspectives in clinical application. Neurological Sciences 24 (Suppl. 2): S146-8, 2003 [abs]
 Piccardi MP et al. Manic-depressive illness: association study with the inositol polyphosphate 1-phosphatase and serotonin transporter genes. Psychiatric Genetics 12:23-27, 2002 [abs]
 Cherchi A, Del Zompo M. “Pharmacology”. In: Headache and Migraine in Childhood and Adolescence, eds. V. Guidetti, G. Russell, M. Sillanpaa, P. Winner, Martin Dunitz, London, pp. 37-47, 2002.
 Zuddas A, Del Zompo M. “Neurochemistry”. In: Headache and Migraine in Childhood and Adolescence, eds. V. Guidetti, G. Russell, M. Sillanpaa, P. Winner, Martin Dunitz, London, pp. 19-36, 2002.
 Bocchetta A et al. Association of personal and familial suicide risk with low serum cholesterol concentration in male lithium patients. Acta Psychiatrica Scandinavica 104: 37-41, 2001 [abs]
 Cherchi A et al. Role of dopaminergic system in migraine. Journal of Headache and Pain 2:S47-S49, 2001.
 Paoletti AM et al. Evidence that cyproterone acetate improves psychological symptoms and enhances the activity of the dopaminergic system in postmenopause. The Journal of Clinical Endocrinology & Metabolism 86, 608-612, 2001.
 Del Zompo M. Dopaminergic hypersensitivity in migraine: Clinical and genetic evidence. Functional Neurology 15 (Suppl. 3): 163-170, 2000 [abs]
 Cherchi A et al. Positive association between dopamine D2 receptor gene and migraine without aura in a Sardinian sample. In: Frontiers in Headache Research vol. 8, “The Genetic of Headache Disorders”, eds. J. Olesen and M-G. Bousser, Lippincott Williams & Wilkins, Philadelphia, pp. 211-215, 2000.
 Bocchetta A et al. Family-based association study between bipolar disorder and DRD2, DRD4 and SERT in Sardinia. American Journal of Medical Genetics (Neuropsychiatric Genetics), 88, 522-526, 1999 [abs]
 Bocchetta A et al. Maternal inheritance of manic depression in hemizygotes for the G6PD-Mediterranean mutation. Indirect evidence for Xq28 transmission in Sardinia”. Psychiatric Genetics 9, 63-68, 1999 [abs]
 Morelli M et al. Induction of fos-like immunoreactivity in the central extended amygdala by antidepressant drugs”. Synapse 31, 1-4, 1999 [abs]
 Del Zompo M et al. Association between dopamine receptor genes and migraine without aura in a Sardinian sample. Neurology 51, 781-786, 1998 [abs]
 Bocchetta A et al. Suicidal behavior on and off lithium prophylaxis in a group of patients with prior suicide attempts. Journal of Clinical Psychopharmacology 18, 384-389, 1998 [abs]
 Lai M et al. Therapy of migraine by modulating dopamine hypersensitivity: its effect on mood and pain. International Journal of Clinical Pharmacological Research 17, 101-103, 1997 [abs]
 Piccardi MP et al. No evidence of association between dopamine D3 receptor gene and bipolar affective disorder. American Journal of Medical Genetics (Neuropsychiatric Genetics) 74, 137-139, 1997 [abs]
 Bocchetta A et al. Carbamazepine augmentation in lithium refractory bipolar patients: a prospective study on long-term prophylactic effectiveness. Journal of Clinical Psychopharmacology 17, 92-96, 1997 [abs]
 Ruiu S et al. Heterogeneity of monoaminergic vesicular carriers: pharmacological evidence using MPP+ as a marker. Life Sciences 59, 1703-1710, 1996 [abs]
 Loi V et al. Sumatriptan and panic-like symptoms. American Journal of Psychiatry 153: 1505, 1996 [abs]
 Bocchetta A et al. Six-year follow-up of thyroid function during lithium treatment. Acta Psychiatrica Scandinavica 94, 45-48, 1996 [abs]
 Del Zompo M et al. Dopamine hypersensitivity in migraine: role in apomorphine syncope. Headache 35, 222-224, 1995 [abs]
 Del Zompo M et al. Thyroid function during carbamazepine. Biological Psychiatry 36, 135-136, 1994 [abs]
 Bocchetta A, Piccardi MP, Del Zompo M. Is bipolar disorder linked to Xq28? Nature Genetics 6, 224, 1994 [abs]
 Bocchetta A et al. A double-blind study of l-sulpiride versus amitriptyline in lithium-maintained bipolar depressives. Acta Psychiatrica Scandinavica 88, 434-439, 1993 [abs]
 Martinelli V et al. An interaction between carbamazepine and fluvoxamine. British Journal of Clinical Pharmacology 36, 615-616, 1993 [abs]
 Bocchetta A et al. Genetic linkage and association studies in affective disorders. In: Psychiatry and Advanced Technologies, Eds. L. Ravizza, F. Bogetto, E. Zanalda, Raven Press Ltd., New York, pp. 283-287, 1993.
 Del Zompo M et al. Selective MPP+ uptake into synaptic dopamine vesicles: possible involvement in MPTP neurotoxicity. British Journal of Pharmacology 109, 411-414, 1993 [abs]
 Vaccari A et al. Differential interaction of 1-methyl-4-phenylpyridinium ion with the putatively vesicular binding site of [3H]tyramine in dopaminergic and nondopaminergic brain regions. Journal of Neurochemistry 60, 758-760, 1993 [abs]
 Bocchetta A et al. The course of thyroid abnormalities during lithium treatment: a two-year follow-up study. Acta Psychiatrica Scandinavica 86, 38-41, 1992 [abs]
 Del Zompo M et al. Localization of MPP+ binding sites in the brain of various mammalian species. Journal of Neural Transmission [P-D Sect] 4, 181-190, 1992 [abs]
 Del Zompo M. Characterization of a putatively vesicular binding site for [3H]MPP+ in mouse striatal membranes. Brain Research 571, 354-357, 1992 [abs]
 Del Zompo M et al. Association and linkage studies of affective disorders. In: “Biological Psychiatry” vol. 2, Eds. G. Racagni, N. Brunello, T. Fukuda, Elsevier Sci. Publ., pp. 446-448, 1991.
 Del Zompo M et al. A double-blind study of minaprine versus amitriptyline in major depression. Neuropsychobiology 24, 79-83, 1991.
 Gessa GL et al. SCH 23390 and psychosis. The Lancet 338, 185-186, 1991.
 Del Zompo M et al. High-affinity binding of [3H]1-methyl-4-phenyl-2,3-dihydropyridinium ion to mouse striatal membranes: putative vesicular location. European Journal of Pharmacology 202, 293-294, 1991.
 Burrai C, Bocchetta A, Del Zompo M. Mania and fluvoxamine. American Journal of Psychiatry 48, 263-1264, 1991.
 Gessa GL et al. Lack of acute antispychotic effect of SCH 23390, a selective dopamine D1 receptor antagonists. The Lancet 337, 854-855, 1991.
 Bocchetta A et al. Thyroid abnormalities during lithium treatment. Acta Psychiatrica Scandinavica 83, 193-198, 1991 [abs]
 Bocchetta A et al. Familial rates of affective illness in Sardinia with special reference to schizoaffective disorder. European Archives of Psychiatry and Clinical Neuroscience 240, 16-20, 1990 [abs]
 Bocchetta A, Del Zompo M. Bipolar affective disorder and heterozygous beta-thalassaemia. American Journal of Psychiatry 147, 1094, 1990.
 Bernardi F, Del Zompo M. Clozapine in idiopathic Parkinson’s disease. Neurology 40, 1151-1152, 1990.
 Del Zompo M. 3H-MPP+ binding sites in mouse brain: pharmacological and biological characterization. Journal of Neurochemistry 54, 1905-1910, 1990 [abs].
 Del Zompo M. Pharmacological characterization of 3H-MPP+ binding sites. In: “Aging Brain and Dementia: New Trends in Diagnosis and Therapy”, Eds. L. Battistin, F. Gerstenbrand, Alan R. Liss, New York, pp. 273-280, 1990.
 Del Zompo M et al. Clinical evidence for a role of dopaminergic system in depressive syndromes. In: “Dopamine and Mental Depression”, Advances in the Biosciences vol. 77, Eds. G.L. Gessa, G. Serra, Pergamon Press, pp. 177-184, 1990.
 Del Zompo M et al. Genetic markers in affective disorders in Sardinia. In: “The Modes of Depression: Psychobiology and Psychodynamics”, eds. L. Ravizza, E. Genazzani, R. Torta, C. Eva, Edizioni Libraria Cortina, Torino, pp. 143-149, 1989.
 Ruiu S et al. Correspondence between 3H-MPP+ binding site and MAO-A enzyme: pharmacological evidences. Pharmacological Research 21 (Suppl. 1): 15-16, 1989.
 Marongiu ME et al. Evaluation of the toxicity of the dopaminergic neurotoxins MPTP and MPP+ in PC12 pheochromocytoma cells: binding and biological studies. Neuroscience Letters 94, 349-354, 1988 [abs]
 Corsini GU et al. Covalent protein binding of a metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to mouse and monkey brain in vitro and in vivo. Biochemical Pharmacology 37, 4163-4169, 1988 [abs]
 Corongiu FP et al. MPTP fails to induce lipid peroxidation in vivo. Biochemical Pharmacology 35, 2251-2253, 1987 [abs]
 Corsini GU et al. Characterization of [3H]MPTP binding sites. In: “Parkinson’s disease”, Advances in Neurology vol. 45, Eds. M.S. Yahr and K.J. Bergmann, , Raven Press, New York, pp. 153-158, 1987.
 Del Zompo M et al. Properties of 3H-MPTP binding sites in human blood platelets. Life Sciences 39, 1885-1892, 1986 [abs]
 Del Zompo M et al. High affinity binding sites for l-methyl-4-phenyl-pyridinium ion (MPP+) are present in mouse brain. European Journal of Pharmacology 129, 87-92, 1986 [abs]
 Corsini GU et al. A reactive metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is formed in rat brain in vitro by type B monoamine oxidase. Journal of Pharmacology and Experimental Therapeutics 238, 648-652, 1986 [abs]
 Corsini GU et al. In vitro MAO type B dependent formation of an alkylating metabolite from 3H-MPTP in rat and monkey brain. In: “MPTP: a neurotoxin producing a parkinsonian syndrome”, eds. S.P. Markey, M. Castagnoli Jr, A.J. Trevor, I.J. Kopin, Academic Press, New York, pp. 371-376, 1986.
 Corsini GU et al. Primate-rodent 3H-MPTP binding differences and biotrasformation of MPTP to a reactive intermediate in vitro. Journal of Neural Transmission 22 (Suppl.), 55-60, 1986 [abs]
 Del Zompo M et al. Involvement of monoamine oxidase enzymes in the action of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine, a selective neurotoxin, in the squirrel monkey: binding and biochemical studies. Brain Research 378, 320-324, 1986 [abs]
 Del Zompo M et al. Dopamine agonists in the treatment of schizophrenia. In: “Progress in Brain Research” vol. 65, Eds. J.M. Van Ree and S. Matthysse, Elsevier Publishers B.V., pp. 41-48, 1986.
 Bocchetta A et al. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correspondence of its binding sites to monoamine oxidase in rat brain, and inhibition of dopamine oxidative deamination in vivo and in vitro. Journal of Neurochemistry 45, 673-676, 1985 [abs]
 Corsini GU et al. Therapeutic efficacy of a partial dopamine agonist in drug-free Parkinsonian patients. Journal of Neural Transmission 64, 105-111, 1985 [abs]
 Del Zompo M et al. Deprenyl selectively inhibits [3H]MPTP binding sites in monkey brain. European Journal of Pharmacology 107, 285-286, 1985.
 Del Zompo M et al. Inhibition of 3H-MPTP binding to rat brain by pargyline. Biochemical Pharmacology 33, 4105-4107, 1984.
 Del Zompo M et al. Peripheral benzodiazepine binding sites in kidney: modifications by diabetes insipidus. Life Sciences 35, 2095-2013, 1984 [abs]
 Del Zompo M et al. Dopaminergic system and clincal aspects of depression. Clinical Neuropharmacology 7 (Suppl.1), 926-927, 1984.
 Del Zompo M et al. Linkage between X-chromosome markers and manic-depressive illness. Two Sardinian pedigrees. Acta Psychiatrica Scandinavica 70, 282-287, 1984 [abs]
 Del Zompo M et al. Prophylactic efficacy of carbamazepine in lithium-resistant affective disorders. In: “Current Trends in Lithium and Rubidium Therapy”, Ed. G.U. Corsini, MTP Press Limited, Lancaster, UK, pp. 325-330, 1984.
 Del Zompo M et al. Lithium treatment in schizoaffective patients. In: “Current Trends in Lithium and Rubidium Therapy”, Ed. G.U.Corsini, MTP Press, Limited, Lancaster, UK, pp. 142-150; 1984.
 Del Zompo M et al. Properties of benzodiazepine binding sites in peripheral tissues. In: “Benzodiazepine Recognition Site Ligands: Biochemistry and Pharmacology”, Eds. G. Biggio and E. Costa, Raven Press, New York, pp. 239-248; 1983.
 Del Zompo M, Post R, Tallman JF. Properties of two benzodiazepine binding sites in spinal cord.Neuropharmacology 22, 115-118, 1983 [abs]
 Del Zompo M et al. Increased paroxysmal activity of partial seizures in man by apomorphine. Psychopharmacology 79, 209-214, 1983 [abs]
 Corsini GU et al. The use of dopamine agonists in the treatment of schizophrenia. Neuropharmacology 20: 1309-1313-1981.
 Del Zompo M et al. Antipsychotic effect of apomorphine: a retrospective study. In: “Apomorphine and Other Dopaminomimetics vol. 2, Clinical Pharmacology”, Eds. G.U. Corsini and G.L. Gessa, Raven Press, New York, pp. 65-76; 1981.
 Corsini et al. Therapeutic efficacy of apomorphine combined with an extracerebral inhibitor of dopamine receptors in Parkinson’s disease. The Lancet i (8122), 954-956, 1979 [abs]
 Corsini GU et al. (-) Sulpiride as a specific antagonist of “low-dose” effects of apomorphine in man. In: “Sulpiride and Other Benzamides”, Eds. P.F. Spano, M. Trabucchi, G.U. Corsini, G.L. Gessa, IBRF Press, Milano, pp. 255-267, 1979.
 Corsini GU et al. Parkinsonism by haloperidol and piribedil. Psychopharmacology 59, 139-141, 1978 [abs]
 Corsini GU et al. Evidence for dopamine receptors in the human brain mediating sedation and sleep. Life Sciences 20, 1613-1618, 1977.
 Corsini GU et al. Sedative, hypnotic and antipsychotic effects of low doses of apomorphine in man. In: “Advances in Biochemical Psychopharmacology”, Eds. E. Costa and G.L. Gessa, Raven Press, New York, vol 16, pp 645-648, 1977.
 Corsini GU et al. Therapeutical efficacy of a combination of apomorphine with Sulpiride or Metoclopramide in Parkinsonism. Psychopharmacology 47, 169-173; 1976.

ATENEI perREGIONE

Log in